Last reviewed · How we verify
bupropion, transdermal nicotine patch
Bupropion and the transdermal nicotine patch, marketed by North Suffolk Mental Health Association, are established treatments in their respective categories. A key strength is the extended market exclusivity secured until 2028 through a key composition patent. The primary risk lies in the competitive landscape, where the absence of detailed information on competitors and trial results may impact market positioning and strategy.
At a glance
| Generic name | bupropion, transdermal nicotine patch |
|---|---|
| Sponsor | North Suffolk Mental Health Association |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment (PHASE2)
- Embedding Comprehensive Smoking Cessation Programs Into Community Clinics (NA)
- Web-based Smoking Cessation Program for Tribal College Students (PHASE3)
- Mobile Contingency Management for Concurrent Abstinence From Alcohol and Smoking (PHASE4)
- Mobile Contingency Management for Marijuana and Tobacco Cessation (NA)
- Comparing Smoking Treatment Programs for Lighter Smokers - 1 (PHASE2)
- Tailored Tobacco Quitline for Rural Veterans (PHASE2)
- Treating Smokeless Tobacco Use in Rural Veterans (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: